Swipe Left For English News
1
获最高评级，评分位列全球前1%
2
连续五年获评晨星Sustainalytics ESG“行业最高评级”及“区域最高评级”
3
引领绿色生物药发展，技术创新赋能健康未来
上海,
2025年7月16日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布，其晨星Sustainalytics ESG评级分数已提升至最高评级——“风险可忽略”等级（negligible-risk），充分彰显了公司在全球医药行业可持续发展领域的领先地位。
在其二维评估框架下，药明生物同时实现全球最低风险敞口与最高风险管理得分，被晨星Sustainalytics评定为“negligible-risk”级别，在全球参评企业中位列前1%。此外，公司已连续五年被晨星Sustainalytics评为 “行业最高评级”和“区域最高评级”企业。
陈智胜
博士
药明生物首席执行官
ESG委员会主席
我们非常荣幸获得晨星Sustainalytics‘negligible-risk’评级。这不仅是药明生物可持续发展能力建设成果的印证，更是对我们在该领域战略投入和卓越实践的高度认可。作为全球绿色生物药解决方案领域的领军者，我们不仅持续追求卓越的ESG表现，并赋能全球合作伙伴，推动其迈向ESG发展新高度。未来，我们将持续携手各方，共同推动整个价值链的负责任发展。
作为联合国全球契约组织（UNGC）和制药供应链倡议组织（PSCI）成员，药明生物积极倡导可持续发展的战略举措并赢得业界广泛认可。公司获得明晟（MSCI）最高AAA ESG评级、EcoVadis“铂金”评级、入选道琼斯可持续发展指数（DJSI）；连续两年荣登CDP水安全管理A级榜单、获得CDP气候变化A-领导力评分；入选富时社会责任指数系列；入选恒生ESG 50指数；ISS ESG评级“最佳”奖章认可，充分彰显了公司在可持续发展领域的卓越表现。
关于晨星Sustainalytics
晨星Sustainalytics是一家领先的 ESG 数据、研究和评级公司，支持世界各地的投资者制定和实施负责任的投资策略。30多年来，该公司一直处于开发高质量、创新解决方案的前沿，以满足全球投资者不断发展的需求。如今，晨星Sustainalytics与数百家世界领先的资产管理公司和养老基金世界卫生组织合作，将 ESG 信息和评估纳入其投资流程。该公司还与数百家公司及其金融中介机构合作，帮助他们考虑政策、做法和资本项目中的物质可持续性因素。晨星Sustainalytics在全球拥有超过40个行业团体的不同多学科专业知识的分析师。更多信息，请访问www.sustainalytics.com.
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2024年12月底，药明生物帮助客户研发和生产的综合项目高达817个，其中包括21个商业化生产项目（不包括新冠项目）。
药明生物以可持续发展为长期业务增长的基石。公司持续推动绿色创新技术，为全球合作伙伴提供先进的端到端绿色CRDMO解决方案，同时在ESG方面不断取得卓越成就。秉承创造共享价值的理念，公司携手利益相关方构建可持续发展生态，通过负责任运营模式推动社会价值与生态效益双提升，实现全价值链的协同赋能。更多信息，请访问：www.wuxibiologics.com
ESG
esg@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics
1
Best ESG rating tier of negligible-risk with a top 1% global ranking score
2
Industry and Regional ESG Top-Rated Company for five consecutive years
3
Leader in Green CRDMO to drive innovation for a healthier future
Shanghai,
July 16, 2025
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has elevated its Morningstar Sustainalytics ESG rating score to the highest negligible-risk tier, demonstrating its leadership in the global pharmaceutical industry.
Sustainalytics is a leading ESG data, research, and ratings firm that supports global investors with their development and implementation of responsible investment strategies. Its 2025 ESG Risk Ratings—covering more than 15,000 companies across different industries worldwide—evaluates over 20 material ESG issues through over 200 indicators and categorizes rating results across five risk levels, from the best negligible to the worst severe.
Under the two-dimensional assessment framework, WuXi Biologics achieved the lowest level of risk exposure and was given the strongest risk management score, placing it in the negligible-risk tier with a top 1% global ranking. In addition, for the fifth consecutive year, the company has been recognized by Morningstar Sustainalytics as an Industry and Regional ESG Top-Rated Company.
Dr. Chris Chen
Chief Executive Officer
Chairman of the ESG Committee
WuXi Biologics
We are very pleased to have achieved the negligible-risk rating from Morningstar Sustainalytics. It is a reflection of and recognition for WuXi Biologics' continuous commitment to enhancing sustainability capabilities. As a global leader in Green CRDMO, we are focused not only on delivering our own ESG excellence but also on enabling partners worldwide to fulfill their ESG commitments, collaborating with all stakeholders to promote responsible practices throughout the entire value chain.
As a participant of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), the company proactively contributes to advocating sustainability and has earned widespread recognitions for its efforts. It has been granted a MSCI AAA rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP Water Security "A list" and given an A- CDP Climate Change leadership-level score since 2023; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.
About Morningstar Sustainalytics
Morningstar Sustainalytics is a leading ESG data, research, and ratings firm that supports investors around the world with the development and implementation of responsible investment strategies. For more than 30 years, the firm has been at the forefront of developing high-quality, innovative solutions to meet the evolving needs of global investors. Today, Morningstar Sustainalytics works with hundreds of the world's leading asset managers and pension funds who incorporate ESG information and assessments into their investment processes. The firm also works with hundreds of companies and their financial intermediaries to help them consider material sustainability factors in policies, practices, and capital projects. Morningstar Sustainalytics has analysts around the world with varied multidisciplinary expertise across more than 40 industry groups. For more information, visit www.sustainalytics.com.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
请点击右下角【爱心】，
并将公众号设为【星标】，
第一时间收到药明生物最新消息
